FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967256265> ?p ?o ?g. }

• W2967256265 abstract "Plasmodium vivax transmission in West Africa, dominant for the Duffy-negative blood group, has been increasingly recognized from both local residents as well as international travelers who contracted P. vivax malaria there. However, the relapsing pattern and sensitivity to antimalarial treatment of P. vivax strains originated from this region are largely unknown. There is evidence that the efficacy of primaquine for radical cure of relapsing malaria depends on host factors such as the hepatic enzyme cytochrome P450 (CYP) 2D6. A 49-year-old Chinese man was admitted to the Shanglin County Hospital in Guangxi Province, China, on December 19, 2016, 39 days after he returned from Ghana, where he stayed for one and a half years. He was diagnosed by microscopy as having uncomplicated P. vivax malaria. Treatment included 3 days of intravenous artesunate (420 mg total), and 3 days of chloroquine (1550 mg total), and 8 days of primaquine (180 mg total). Although parasites and symptoms were cleared rapidly and he was malaria-negative for almost two months, he suffered four relapses with relapse intervals ranging from 58 to 232 days. The last relapse occurred at 491 days from his first vivax attack. For the first three relapses, he was treated similarly with chloroquine and primaquine, sometimes supplemented with additional artemisinin combination therapies (ACTs). For the last relapse, he was treated with intravenous artesunate, 3 days of an ACT, and 7 days of azithromycin, and had remained healthy for 330 days. Molecular studies confirmed P. vivax infections for all the episodes. Although this patient was diagnosed to have normal glucose-6-phosphate dehydrogenase (G6PD) activity, his CYP2D6 genotype corresponded to a *2A/*36 allele variant suggesting of an impaired primaquine metabolizer phenotype. This clinical case suggests that P. vivax malaria originating from West Africa may produce multiple relapses extending beyond one year. The failures of primaquine as an anti-relapse therapy may be attributed to the patient’s impaired metabolizer phenotype of the CYP2D6. This highlights the importance of knowing the host G6PD and CYP2D6 activities for effective radical cure of relapsing malaria by primaquine." @default.
• W2967256265 created "2019-08-22" @default.
• W2967256265 creator A5003208163 @default.
• W2967256265 creator A5005484398 @default.
• W2967256265 creator A5007944766 @default.
• W2967256265 creator A5030015470 @default.
• W2967256265 creator A5031600929 @default.
• W2967256265 creator A5033269423 @default.
• W2967256265 creator A5035680760 @default.
• W2967256265 creator A5038736889 @default.
• W2967256265 creator A5075323066 @default.
• W2967256265 creator A5076750976 @default.
• W2967256265 creator A5078259658 @default.
• W2967256265 creator A5088965011 @default.
• W2967256265 creator A5089859146 @default.
• W2967256265 date "2019-08-09" @default.
• W2967256265 modified "2023-10-18" @default.
• W2967256265 title "Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report" @default.
• W2967256265 cites W1515527087 @default.
• W2967256265 cites W1924088672 @default.
• W2967256265 cites W1969834934 @default.
• W2967256265 cites W1970842338 @default.
• W2967256265 cites W1978222899 @default.
• W2967256265 cites W1984131408 @default.
• W2967256265 cites W1989185921 @default.
• W2967256265 cites W1999520705 @default.
• W2967256265 cites W2000469896 @default.
• W2967256265 cites W2007202860 @default.
• W2967256265 cites W2023031926 @default.
• W2967256265 cites W2048537115 @default.
• W2967256265 cites W2051180136 @default.
• W2967256265 cites W2072894930 @default.
• W2967256265 cites W2096415021 @default.
• W2967256265 cites W2098867544 @default.
• W2967256265 cites W2100970784 @default.
• W2967256265 cites W2107071499 @default.
• W2967256265 cites W2112395530 @default.
• W2967256265 cites W2124740902 @default.
• W2967256265 cites W2134054893 @default.
• W2967256265 cites W2137952006 @default.
• W2967256265 cites W2158149195 @default.
• W2967256265 cites W2159923524 @default.
• W2967256265 cites W2172920258 @default.
• W2967256265 cites W2184357998 @default.
• W2967256265 cites W2199277501 @default.
• W2967256265 cites W2278941756 @default.
• W2967256265 cites W2588218371 @default.
• W2967256265 cites W2793635060 @default.
• W2967256265 cites W2891945121 @default.
• W2967256265 cites W2900782681 @default.
• W2967256265 cites W2910820964 @default.
• W2967256265 cites W2912813940 @default.
• W2967256265 cites W2945134120 @default.
• W2967256265 cites W2950607694 @default.
• W2967256265 cites W87464560 @default.
• W2967256265 doi "https://doi.org/10.1186/s12879-019-4357-9" @default.
• W2967256265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6688248" @default.
• W2967256265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31399061" @default.
• W2967256265 hasPublicationYear "2019" @default.
• W2967256265 type Work @default.
• W2967256265 sameAs 2967256265 @default.
• W2967256265 citedByCount "14" @default.
• W2967256265 countsByYear W29672562652019 @default.
• W2967256265 countsByYear W29672562652020 @default.
• W2967256265 countsByYear W29672562652021 @default.
• W2967256265 countsByYear W29672562652022 @default.
• W2967256265 countsByYear W29672562652023 @default.
• W2967256265 crossrefType "journal-article" @default.
• W2967256265 hasAuthorship W2967256265A5003208163 @default.
• W2967256265 hasAuthorship W2967256265A5005484398 @default.
• W2967256265 hasAuthorship W2967256265A5007944766 @default.
• W2967256265 hasAuthorship W2967256265A5030015470 @default.
• W2967256265 hasAuthorship W2967256265A5031600929 @default.
• W2967256265 hasAuthorship W2967256265A5033269423 @default.
• W2967256265 hasAuthorship W2967256265A5035680760 @default.
• W2967256265 hasAuthorship W2967256265A5038736889 @default.
• W2967256265 hasAuthorship W2967256265A5075323066 @default.
• W2967256265 hasAuthorship W2967256265A5076750976 @default.
• W2967256265 hasAuthorship W2967256265A5078259658 @default.
• W2967256265 hasAuthorship W2967256265A5088965011 @default.
• W2967256265 hasAuthorship W2967256265A5089859146 @default.
• W2967256265 hasBestOaLocation W29672562651 @default.
• W2967256265 hasConcept C126322002 @default.
• W2967256265 hasConcept C142724271 @default.
• W2967256265 hasConcept C185032368 @default.
• W2967256265 hasConcept C190139176 @default.
• W2967256265 hasConcept C190612196 @default.
• W2967256265 hasConcept C203014093 @default.
• W2967256265 hasConcept C2776120307 @default.
• W2967256265 hasConcept C2776793103 @default.
• W2967256265 hasConcept C2777425658 @default.
• W2967256265 hasConcept C2778048844 @default.
• W2967256265 hasConcept C2778059366 @default.
• W2967256265 hasConcept C2778371730 @default.
• W2967256265 hasConcept C2779997623 @default.
• W2967256265 hasConcept C71924100 @default.
• W2967256265 hasConcept C90924648 @default.
• W2967256265 hasConceptScore W2967256265C126322002 @default.
• W2967256265 hasConceptScore W2967256265C142724271 @default.
• W2967256265 hasConceptScore W2967256265C185032368 @default.

• next